Announcements Trials

Browse Landscape

Status

Terminated 1 Completed 1 Active not recruiting 1

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Motor Activity 9 Neoplasms 4 Breast Neoplasms 3 Weight Loss 2 Ventricular Dysfunction, Left 1 Urinary Incontinence 1 Sexual Dysfunction, Physiological 1 Sarcoma 1 Rectal Neoplasms 1 Prostatic Neoplasms 1 Polycystic Ovary Syndrome 1 Ovarian Neoplasms 1 Melanoma 1 Lymphoma 1 Leukemia 1 Insulin Resistance 1 Hypoxia 1 Hematologic Neoplasms 1 Heart Failure 1 Head and Neck Neoplasms 1 Fecal Incontinence 1 Fatigue 1 Cardiotoxicity 1 Carcinoma, Renal Cell 1 Cachexia 1 Brenner Tumor 1 Breast Diseases 1 Brain Neoplasms 1 Bone Metastases 1 Body Weight 1

Interventions

pembrolizumab 51 Ipilimumab 49 Cyclophosphamide 43 Nivolumab 40 aldesleukin 30 Interleukin-2 23 Vemurafenib 20 fludarabine 19 Temozolomide 18 fludarabine phosphate 15 dabrafenib 15 trametinib 12 Radiosurgery 10 Dacarbazine 10 CTLA-4 Antigen 10 spartalizumab 9 cobimetinib 9 binimetinib 9 Radiotherapy 9 poly ICLC 7 encorafenib 7 Paclitaxel 7 atezolizumab 6 Introns 6 Biopsy 6 montanide ISA 51 5 Carboplatin 5 epacadostat 4 MART-1 Antigen 4 Interferon alpha-2 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Melanoma × Exercise × Clear all

NCT03464604 2022-11-23

Melanoma Accuracy Study; Phase 2

Nova Scotia Health Authority

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡